23 October 2020
The Vector State Research Center of Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing has detected over 80 mutations of the coronavirus yet they do not affect the effectiveness of the developed vaccine, the center’s General Director Rinat Maksyutov reported on Wednesday (October 21).
“The Vector Center is additionally conducting extensive studies of the genetic variability of the novel coronavirus in all Russian regions. <…> We constantly perform whole-genome sequencing and detect possible mutant variants. To date, we have detected over 80 nucleotide substitutions which are not included in international databases. But these changes are not critical and do not influence the effectiveness of the peptide vaccine developed,” he said at the 17th annual meeting of the Valdai International Discussion Club.
The coronavirus vaccine developed by Siberia’s Vector Center is safe for people with allergies or chronic conditions and seniors, the general director of the center said Wednesday. “The vaccine is fully safe both for healthy volunteers, people with chronic conditions or allergies and seniors.”
The trials showed that the vaccine has high immunogenicity properties. “We confirmed that the peptide vaccine showed both the high safety profile and high immunogenicity in the conducted clinical trials involving 100 volunteers as all volunteers who received the shot had an immune response. This sampling gives us proof of the protective effectiveness in the framework of the conducted epidemiological research,” Maksyutov pointed out.
Print2021 in Focus: Pharm Exec’s Annual Industry Outlook
15 January 2021
Research Eye stem cell transplant to treat blindness bolsters retinal function in monkeys
15 January 2021
Harnessing the power of a digital assistant to accelerate patient access
14 January 2021
A COVID-19 treatment candidate that fuses tiny antibodies from llamas and alpacas shows promise
14 January 2021